Lung Cancer Screening With Low-dose CT Scan in Women : Implementation Study

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age50-74
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

The purpose of this study is to determine whether reading of low-dose thoracic CT scans can be done by a single general radiologist who has been trained to lung cancer screening, and will evaluate the performance in comparison with double reading by experts.

The study will enroll women between 50 and 74 years old, at risk for lung cancer due to their smoking history.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Women aged from 50 to 74 years

who had smoked at least 20 pack years and quit less than 15 years ago

Had given their consent and accepted the need for a 2-year follow-up

Affiliated to the social security system

Disqualifiers

Presence of clinical symptoms suggesting malignancy (weight loss, hemoptysis) or ongoing infection (cough with fever)

Evolving cancer

History of lung cancer

A 2-year follow-up not possible

Trial design

Design model

Single group

Treatments tested in this trial

  • Low-dose computed tomography of the chest

    Procedure/Surgery

    Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules

Treatment groups

2,635 Participants
are divided into 1 treatment group
Group A: ProcedureOther 1 intervention

Trial outcomes

Primary outcomes

1

Performance of trained radiologists for lung cancer screening

Sensitivity, specificity, predictive values compared to double reading by experts

Time frame
2 years

Secondary outcomes

1

Effectiveness of screening

Proportion of participants with a positive screening test and proportion of confirmed diagnosis of cancer

Time frame
2 years
2

Analysis of the diagnostic performance of the reading without detection software, in order to assess its incremental value

For the general population and for the COPD population. Sensitivity, specificity, predictive values and likelihood ratios of the initial reading compared to the expert readings, using histological diagnosis as gold standard for positive screens and stability at 2 years for negative screens

Time frame
2 years
3

Analysis of the performance of a reading by detection software alone

For the general population and for the COPD population. Sensitivity, specificity, predictive values and likelihood ratios of artificial intelligence alone

Time frame
2 years
4

Analysis of the concordances of the different readings

Kappa concordance coefficient between the different readings

Time frame
2 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assistance Publique - Hôpitaux de Paris

Lead sponsor

Ministère de la Santé et des Solidarités

Collaborator

National Cancer Institute, France

Collaborator

URC-CIC Paris Descartes Necker Cochin

Collaborator